RG2417: Completed Phase IIb enrollment

Repligen completed enrollment of 175 patients in a double-blind, placebo-controlled, dose-escalation, U.S. Phase IIb trial evaluating twice-daily 500 mg oral RG2417 for 8 weeks. ...